- Blood Sugar
- Clinical Studies
- Complementary Medicine
- Diabetes and Men
- Erectile Dysfunction
- Food and Nutrition
- Insulin Pumps
- Meters and Test Strips
- Product Recalls
- Type 1
- Type 2
- Weight Loss Surgery
June 16, 2016 (Health Day) — Teens with type 2 diabetes may have differences in gray matter in their brains, a small study found.
Researchers conducted brain scans on 20 teens with type 2 diabetes and 20 teens without the blood sugar disease. Those with diabetes had less gray matter in six regions in their brains, and more gray matter in three regions. Some of these affected regions are involved in see...
June 16, 2016 (Physician's Briefing) — Liraglutide (Victoza) cuts the risk of heart attack and stroke in type 2 diabetes patients, according to a study published online June 14 in the New England Journal of Medicine. The research was published to coincide with the American Diabetes Association's 76th Scientific Sessions, held from June 10 to 14 in New Orleans.
The study included 9,340 adults from 32 countries who had type 2 diabetes and a high risk of cardiovascular disease. About half took lira...
June 15, 2016 (HealthDayNews) — For patients with type 2 diabetes, remission after bariatric surgery is associated with a reduced risk of microvascular disease, even after subsequent relapse, according to a study published online June 6 in Diabetes Care.
Karen J. Coleman, Ph.D., from Kaiser Permanente Southern California in Pasadena, and colleagues conducted a retrospective observational cohort study involving 4,683 patients with type 2 diabetes who underwent bariatric surgery from 2001 through ...
June 15, 2016 (mHealthIntelligence) — Healthcare providers are finding that the best mHealth program doesn't stand on its own.
A study launched by digital health company WellDoc finds that a combination of digital tools and in-person coaching can help those diagnosed with type 2 diabetes better manage their health. The results offer strong support for a patient-centered medical home concept that ties together providers, payers and the patient's support networ...
June 13, 2016 (Medscape) — A post hoc analysis of the Examination of Cardiovascular Outcomes With Alogliptin versus Standard of Care (EXAMINE) trial with the type 2 diabetes drug alogliptin (Nesina, Takeda), an oral dipeptidyl peptidase–4 (DPP-4) inhibitor, has shown that the risk of cardiovascular death was higher if patients in the trial had first experienced a nonfatal cardiovascular event.
This was particularly true of hospitalization for heart failure (HF) — those patients were almost five times more lik...
June 13, 2016 (Physician's Briefing) — Genetic variants in CYP2C8 and SLCO1B1 impact the therapeutic response to rosiglitazone in patients with type 2 diabetes, according to a study published online June 6 in Diabetes Care.
Adem Y. Dawed, M.P.H., from the University of Dundee in the United Kingdom, and colleagues genotyped 833 Scottish patients with type 2 diabetes treated with pioglitazone or rosiglitazone. The authors examined the correlation between variants in the SLCO1B1 and CYP2C8 genes (i...
June 13, 2016 (Endocrinology Advisor) — When used in the home setting, a bihormonal "bionic pancreas" was associated with reductions in mean blood glucose and hypoglycemia in adults with type 1 diabetes, as compared with conventional insulin pump therapy.
The results were reported by Edward Damiano, PhD, professor of biomedical engineering at Boston University in Massachusetts, at the American Diabetes Asso...
Dynavax Presents New Efficacy Data on Hepatitis B Vaccine, HEPLISAV-B(TM), in Adults With Type 2 Diabetes at ADA Scientific Sessions
June 13, 2016 (Dynavax) — Dynavax Technologies Corporation (NASDAQ: DVAX) today announced preliminary results from a pivotal Phase 3 trial demonstrating that HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] provided a significantly higher rate of seroprotection than Engerix-B, an approved hepatitis B vaccine, in adults with type 2 diabetes mellitus. The d...
June 13, 2016 (Newswise) — An international observational study led by Columbia University researchers has uncovered widespread differences in the treatment of patients with common chronic diseases, including type 2 diabetes, hypertension, and depression. Using data from 250 million patient records in four countries, the study demonstrates the feasibility of performing large-scale observational research to obtain information about clinical practice among diverse groups of patients.
Findings from th...
Bayshore Community Hospital Diabetes Self-Management Education Program Earns Re-Certification by American Diabetes Association
June 13, 2016 (Newswise) — The Diabetes Self-Management program at Bayshore Community Hospital is pleased to announced that it has received re-certification from the American Diabetes Association (ADA) for the fourth time for meeting the national standard. The ADA process requires the submission of an annual status report, additional documentation, as well as an unannounced inspection. Hospitals must re-apply every four years.
The program is provided by a certified diabetes educator and registered ...